Dyslipidemia, an abnormal lipid profile, is a significant risk factor for cardiovascular disease. Understanding its pathophysiology and management is crucial for clinicians to deliver effective patient care.
Dyslipidemia is characterized by elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and reduced high-density lipoprotein cholesterol (HDL-C). Genetic factors, diet, and lifestyle significantly contribute to its development. These abnormalities can lead to atherosclerosis, resulting in cardiovascular diseases.
Diagnosis relies on lipid profiling via fasting blood samples. The American Heart Association recommends adults over 20 have their cholesterol checked every 4-6 years. More frequent testing may be required for individuals with risk factors such as obesity, diabetes, or a family history of dyslipidemia.
Treatment focuses on reducing LDL-C levels and cardiovascular risk. Lifestyle modifications, including diet, physical activity, and weight management, are first-line strategies. Pharmacotherapy, such as statins, is recommended for patients who fail to achieve target LDL-C levels with lifestyle changes alone. Combination therapy with other lipid-lowering agents may be necessary for high-risk patients.
Emerging therapies, including PCSK9 inhibitors and novel RNA-based therapies, offer potential for improved outcomes. However, their cost-effectiveness and long-term safety remain to be established.
Understanding and managing dyslipidemia requires a comprehensive approach, including early diagnosis, lifestyle modifications, and appropriate pharmacotherapy. Emerging therapies offer promising avenues for future management. Ongoing research is crucial to refine treatment strategies and improve patient outcomes in dyslipidemia.
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
TULSA Is Effective in Long-Term Prostate Cancer Control.
3.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
4.
In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".
5.
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
1.
Molecular Matching for Individualized Blood-Disorder Therapy
2.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
3.
Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship
4.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation